Group 1 - The core viewpoint of the article highlights that Junshi Biosciences has been recognized as a future unicorn in the biotechnology sector, particularly for its innovative cell therapy and drug development in the field of solid tumors [1] - The "2025 Future Unicorn" list, published by Chuangyebang, serves as an important indicator of the evolution of China's innovation landscape, with a focus on long-term growth logic [1] - The selected companies, including Junshi Biosciences, were evaluated based on five core dimensions: founding team, technological barriers, commercialization capability, capital attractiveness, and growth momentum [1] Group 2 - Junshi Biosciences has centered its core strategy around TIL therapy, aiming to transition this disruptive cell therapy from "efficacy" to "practicality" [2] - The company has over ten research pipelines, including the world's first natural TIL therapy GC101, which is currently in critical Phase II clinical trials, and the innovative non-viral vector gene-modified TIL therapy GC203 in Phase I clinical trials [2] - These therapies have shown excellent clinical efficacy across various advanced solid tumors, with some patients achieving complete tumor clearance and maintaining no evidence of disease for over four years [2] Group 3 - Junshi Biosciences is advancing its industrialization efforts with a new TIL cell industrialization base in Shanghai, covering over 16,000 square meters, which includes production, quality, data, and operational centers [3] - The company completed a C-round financing of 137 million yuan, attracting investment from specialized institutions in the life sciences sector, indicating strong capital attractiveness [3] - The current investment climate is more pragmatic, with a focus on cost and complexity, which aligns with Junshi Biosciences' efforts to tackle challenges in cell therapy [3] Group 4 - The recognition of Junshi Biosciences amidst the AI and hardware trends of 2025 underscores the significance of companies dedicated to cell therapy [4]